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SUMMARY 
Mycobacterium abscessus (MABS) infection represents significant management challenge in 
cystic fibrosis (CF) patients. This retrospective study (2005-2016) aims to determine the 
prevalence of the subspecies of MABS isolated from CF patients, to evaluate the persistence 
over the years of a single subspecies of MABS and to correlate mutations responsible for 
macrolides and amikacin resistance with MIC values. 
We investigated 314 strains (1 isolate/patient/year) isolated from the lower respiratory tract of 
51 chronically infected CF patients. Sequencing of rpoB gene was performed to identify the 
MABS subspecies. The erm(41) gene was sequenced to differentiate the strains with and 
without inducible macrolide resistance. Regions of 23S and 16S rRNA were sequenced to 
investigate mutations responsible for constitutive resistance to macrolides and 
aminoglycosides, respectively. Antibiotic susceptibility, using commercial microdilution 
plates, was evaluated according to CLSI. 
     
M. abscessus subsp. abscessus accounted for 64% of the isolates, bolletii subspecies for 16% 
and massiliense subspecies for 20%. All the massiliense strains presented truncated erm(41) 
gene while 12 abscessus strains presented the mutation T28->C in the erm(41) gene, which 
makes it inactive. The 23S rRNA analysis did not show constitutive resistance to macrolides 
in any strain. Mutation of the 16S rRNA gene was highlighted in 2 strains out of 314, in 
agreement with high MIC values.  
The correct identification at the subspecies level and the molecular analysis of 23S rRNA, 16S 
rRNA and erm gene is useful to guide the treatment strategy in patients with M. abscessus lung 
infection.   
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INTRODUCTION 
Mycobacterium abscessus (MABS) and the species belonging to Mycobacterium avium 
complex are the Non-Tuberculous Mycobacteria (NTMs) isolated with increasing frequency 
from patients with cystic fibrosis (CF), with a prevalence ranging from 3.8% to 22.6% (Torrens 
et al., 1998). In a recent study a significantly more severe decline of lung functionality has 
been reported in CF patients with chronic MABS infection than in those infected by other NTM 
species (Esther et al., 2010). 
Given the ubiquitous nature of NTMs, isolation of an NTM from respiratory specimen is not 
synonymous with disease, nor it is necessarily an indication to initiate treatment. Current 
American Thoracic Society and Infectious Diseases Society of America (ATS/IDSA) criteria 
for the diagnosis of NTM lung disease call for the presence of 2 or more positive cultures, in 
the setting of compatible symptoms and radiographic findings and the exclusion of other 
diseases (Torrens et al., 1998). 
MABS, whose involvement in lung infections is increasing worldwide (Lai et al., 2010; 
Thomson and NTM working group at Queensland TB Control Centre and Queensland 
Mycobacterial Reference Laboratory, 2010), in particular in CF patients (Griffith, 2003; 
Olivier et al., 2003), is characterized by resistance to most of the antibiotics potentially active 
on rapid growing mycobacteria (RGM). MABS can cause severe lung infections and has 
proven to be a serious threat to patients with CF and a challenge for clinicians due to difficulties 
in timely diagnosis and complex multidrug treatment regimens (Nessar et al., 2012),8. 
In recent years, whole genome sequencing has produced substantial evidence of the presence, 
within the MABS, of three subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. 
bolletii and M. abscessus subsp. massiliense differing for the spectrum of resistance to 
antibiotics (Bryant et al., 2013; Tortoli et al., 2016).  
The isolation of MABS from the sputum of CF patients is technically challenging as it is often 
hampered by the concurrent overgrowth of Pseudomonas aeruginosa or by the heavy 
decontamination procedure required by samples from CF patients; it follows that the 
prevalence of MABS is probably underestimated.   
Although to date its role in the decline in lung functionality in CF patients is unclear, some CF 
patients have chronic MABS infection while in others it occurs intermittently. At times patients 
with apparent chronic infection are instead infected, at different times, by different strains even 
belonging to different subspecies.  
The present retrospective study investigates MABS strains isolated from pulmonary specimens 
of CF patients attending the CF Regional Reference Centre (CRRFC) of Milan between 2005 
     
and 2016. Objectives of the study, restricted to CF patients with chronic MABS infection, 
include: determination of the prevalence of the different subspecies, evaluation of the 
persistence over the years of a single subspecies of MABS or the alternation of different 
subspecies, and the evaluation of the correlation between mutations responsible for macrolides 
and amikacin resistance and the minimum inhibitory concentrations (MIC) detected by broth 
microdilution.  
MATERIALS AND METHODS 
Study population 
A total of 314 MABS strains, collected between 2005-2016 (1 isolate/patient/year stored at -
80°C) were obtained from respiratory specimens (bronchial aspirates, sputum or 
nasopharyngeal aspirates) of 51 chronically infected CF patients (31 males). The specimens 
were collected during the quarterly routine check-up provided by the protocol used in the Milan 
CF center, in agreement with national and international guidelines (Griffith et al., 2007; Floto 
et al., 2016; Haworth et al., 2017). 
Microbiological analysis  
Our laboratory, in agreement with literature data, has introduced in its routine a culture system 
for rapid growing of mycobacteria based on the use of Burkholderia cepacia selective agar 
(BCSA) (Esther et al., 2011). Colony morphology was investigated and the colonies were 
differentiated as rough or smooth. An initial presumptive identification of species was 
performed using matrix-assisted laser desorption/ionization time of flight (MALDI-TOF, 
VITEK-MS Mycobacterium/Nocardia kit, BioMérieux). The strains of MABS were frozen at 
-80 °C for subsequent molecular analysis. 
Molecular characterization of MABS strains  
The identification of the MABS subspecies was performed by partial amplification and 
sequencing of the housekeeping gene rpoB using the primers rpoB-F: 
GGCAAGGTCACCCCGAAGGG and rpoB-R: AGCGGCTGCTGGGTGATCATC that 
allowed us to sequence a tract of about 700 pb (Adékambi et al., 2006). The sequences obtained 
were compared with those of type strains of the three subspecies of MABS available in 
GenBank.  
Detection of mutations responsible for resistance  
The erm(41) gene, responsible for inducible resistance to macrolides, was sequenced by using 
the primers: erm-F: GACCGGGGCCTTCTTCGTGAT and erm-R: 
     
GACTTCCCCGCACCGATTCC to differentiate wild type strains from the ones with erm(41) 
gene either truncated or harboring the T28C mutation (Kim et al., 2010).   
The 19-F: GTAGCGAAATTCCTTGTCGG and 21-R: TTCCCGCTTAGATGCTTTCAG 
primers were used to amplify the peptidyltransferase region of the 23S rRNA gene, to search 
the mutations (A2058C, A2058G, A2059C, A2059G) responsible for constitutive resistance to 
macrolides (Meier et al., 1994).  
The 16S rRNA gene was sequenced with the 16S-f2: CAGCAGCCGCGGTAATAC and 1541-
r: CACCTTCCGGTACGGCTA primers (Prammananan et al., 1998), targeting the variable 
region around nucleotide 1000 involved in mutations responsible for amikacin-resistance 
(A1408G and C1409T) (Nessar et al., 2011). The sequences obtained were compared to the 
wild type gene sequence of MABS deposited in GenBank database.  
Antimicrobial susceptibility testing   
MIC values were measured following the recommendations of Clinical Laboratory Standards 
Institute (Woods et al., 2011; Clinical & Laboratory Standards Institute, 2019) using a broth 
(cation-adjusted Mueller-Hinton) microdilution (RAPMYCO SENSITITRE®). The following 
9 antibiotics were tested: Amikacin (AMI), Cefoxitin (FOX), Ciprofloxacin (CIP), 
Clarithromycin (CLA), Doxycycline (DOX), Imipenem (IMI), Linezolid (LZD), Moxifloxacin 
(MXF), Sulfamethoxazole-trimethoprim (SXT). The plates were read after five days of 
incubation and the MIC of clarithromycin was read again after an incubation period of 14 days. 
For quality control purposes, M. peregrinum ATCC 700686 and Staphylococcus aureus ATCC 
29213 were used. Additionally, MIC50 and MIC90 values were derived from the MIC 
distribution for each antibiotic. 
Statistical analysis 
Descriptive statistics including MIC median, MIC50 and MIC90, were performed for each drug. 
Pearson’s chi-squared test and Fisher’s exact test statistics were used to assess proportion of 
resistant profiles of M. abscessus, M. Bolletii and M. massiliense. P-values were two-sided and 
P<0.05 was considered statistically significant. All analyses were performed using the open 
source software R version 3.5.1 (http://www.R-project.org) 
RESULTS 
Distribution of the MABS subspecies in the CRRFC of Milan  
Among 51 chronically infected patients, 314 isolates were collected during the period 2005-
2016. According to rpoB gene sequencing, M. abscessus subsp. abscessus accounted for 64%, 
M. abscessus subsp. bolletii for 16% and M. abscessus subsp. massiliense for 20%.   
     
Evaluation over time of the MABS subspecies isolated from CF patients  
As shown in Figure 1, a large majority of patients (90%) were persistently infected by the same 
subspecies of MABS. Only 5 patients (10%) had either a co-infection or alternation of 
infections by different subspecies (abscessus and bolletii or abscessus and massiliense).  
Analysis of the erm gene  
Out of 202 M. abscessus subsp. abscessus, 190 (94%) presented wild-type (WT) erm(41) gene 
which was able to confer inducible resistance to macrolides. The 12 remaining (6%) showed 
the mutation T28C responsible for inactivation of erm gene, which was therefore unable to 
induce resistance (Table 1, 2).  
All the 52 M. abscessus subsp. bolletii isolates had WT erm gene, therefore responsible for 
inducible resistance (Table 1, 2). 
All the isolates of M. abscessus subsp. massiliense (60 strains) showed a truncated erm gene, 
thus excluding the possibility of inducible macrolide resistance (Table 1, 2).  
Analysis of the 16S and 23S rRNA genes   
A->G mutation at positions 1408 of the 16S rRNA gene, responsible for amikacin resistance, 
was detected in two strains of the subspecies abscessus.  
None of the clinical isolates showed in 23S rRNA gene any of the mutations 
(A2058C/A2058G/A2059C/A2059G) responsible for constitutive macrolide resistance (Table 
1, 2).  
Antimicrobial susceptibility testing   
Antimicrobial susceptibility testing confirmed the multidrug-resistance of MABS; in fact, the 
strains showed resistant phenotype to most antibiotics (Nie et al., 2014; Mougari et al., 2017; 
Kusuki et al., 2018).   
The drug susceptibility patterns of MABS, including the MIC50/MIC90 values, are presented 
in Table 3. Amikacin was the most active; the resistance rate to amikacin was 1% (2/202) for 
the subspecies abscessus while no resistance was detected among the subspecies massiliense 
and bolletii. The difference between the subspecies (P=1) was not significant. 
Resistance rates to trimethoprim/sulfamethoxazole and imipenem (IMI P=0.0729) were 
significantly higher (SXT P<0.001; IMI P=0.0729) in the subspecies abscessus (SXT R=86%, 
IMI R=39%) than in massiliense (SXT R=52%, IMI R=25%) and bolleti (SXT R=63%, IMI 
R=27%).  
Almost all isolates were resistant (R>88%) to doxycycline and no significant difference was 
detected between the three subspecies (P=0.6488). 
     
Resistance rates to moxifloxacin and ciprofloxacin were equally high in the subspecies 
abscessus (CIP R=55%; MXF R=60%), massiliense (CIP R=62%; MXF R=68%) and bolletii 
(CIP R=52%; MXF R=50%). Almost all the isolates of the three subspecies were susceptible 
to linezolid (S>93%).   
Resistance rates to cefoxitin were low (R<3%) in the three subspecies with no significant 
differences (P=0.2636). 
For clarithromycin, 6% (12/202) of the isolates of the subsp. abscessus were still susceptible at 
14 days. The remaining 94% (190/202) were susceptible at 5 days but resistant at day 14, in 
agreement with the WT erm gene. Similarly, 100% (52/52) of the strains of the subsp. bolletii, 
all presenting WT erm gene, were susceptible at day 5, but resistant at day 14. On the other 
hand, all the strains of the subsp. massiliense remained susceptible at day 14, as expected, 
because of the truncated erm gene (100% of the strains showed MIC equal to 0.5 µg/mL) (Table 
1, 2).  
DISCUSSION 
To date, the CRRFC and the CF Adult Section of Milan (IRCCS Cà Granda Foundation, 
Ospedale Maggiore Policlinico), comprises 892 patients, aged between less than one month to 
74 years.  
In our twelve-year surveillance (2005-2016) the number of CF patients in the center, as well as 
the prevalence of MABS infection, has progressively increased from 3.5% (2005) to 5.2% 
(2016). The factors that may have contributed to such increase include: 1) the use, since 2010, 
of Burkholderia cepacia Selective Agar, which makes it much easier to isolate RGM, including 
MABS; 2) the implementation of genetic sequencing for identification; 3) the lengthening of 
life expectancy of patients, and 4) the acquisition, from other Italian CF Centers, of patients 
previously infected by NTM including MABS.   
Several studies reported the proportion of the three subspecies among MABS isolates. Out of 
40 patients monitored at the National Institutes of Health (Bethesda, MD), the prevalence of 
M. abscessus subsp. massiliense and M. abscessus subsp. bolletii was 28% and 5%, 
respectively (Zelazny et al., 2009). In the Netherlands, 21% of clinical isolates of M. abscessus 
were identified as M. abscessus subsp. massiliense and 15% as M. abscessus subsp. Bolletii 
(van Ingen et al., 2009). In France, M. abscessus subsp. massiliense and M. abscessus subsp. 
bolletii accounted for 22% and 18%, respectively, of 50 CF patients infected by MABS (Roux 
et al., 2009). In Korea, half (47%) of M. abscessus clinical isolates were identified as M. 
abscessus subsp. massiliense while the prevalence of M. abscessus subsp. bolletii was low (2%) 
     
(Kim et al., 2008). The present study included 51 patients with chronic MABS lung disease, 
and molecular identification revealed that in CF patients attending our center the infection was 
more frequently due to M. abscessus subsp. abscessus (64%), followed by M. abscessus subsp. 
massiliense (20%) and M. abscessus subsp. bolletii (16%). The alternation of the subspecies 
responsible for infection was observed in only five patients (10%), while in the other patients 
the subspecies remained unchanged over time (Figure 1). The prevalence of the three M. 
abscessus subspecies did not significantly differ from that reported in other case studies 
(Zelazny et al., 2009; O’Driscoll et al., 2016).  
Lee et al. (Lee et al., 2014), reported a low frequency of 23S rRNA and 16S rRNA mutants, 
only 3.8% of strains possessed rrl mutation (Nessar et al., 2011) while the mutation A1408G 
of the 16S rRNA gene was present in 1% of MABS strains. Prammananan et al. (Prammananan 
et al., 1998) reported that M. abscessus subsp. abscessus strains mutated in the 16S rRNA gene 
had high MIC values (>64 µg/ml) of amikacin and were isolated from the patients who had 
received aminoglycoside therapy.  
In our Center, we detected the A->G mutation at positions 1408 of the 16S rRNA gene, 
responsible for amikacin resistance, in 2 strains of the subspecies abscessus (MIC values > 64 
µg/ml). None of our clinical isolates showed, in 23S rRNA gene, any of the mutations 
responsible for constitutive macrolide resistance.  
In this study, amikacin was the most active antimicrobial agent against MABS species, 
showing a 99% overall susceptibility rate. After amikacin, linezolid was the second most 
effective antimicrobial agent, with 93% susceptibility rate.  
Although prior studies have reported a variable susceptibility rate for linezolid ranging from 
32.0% to 97.0% (Yang et al., 2003; Chua et al., 2015), the majority of the strains of MABS 
species are susceptible to linezolid.  
Linezolid represents the best choice in association with amikacin. Resistance rates to 
trimethoprim/sulfamethoxazole (SXT P<0.001) and imipenem (IMI P=0.0729) were higher in 
the subsp. abscessus than in massiliense and bolletii.  
Resistance rates to cefoxitin was low (R<3%) in MABS and there was no significant difference 
in resistance rates among the three subspecies (P=0.2636). 
Contrary to our results, one Australian study reported that the subspecies massiliense (27.8%) 
was more resistant to cefoxitin than abscessus (10.0%) (Chua et al., 2015). 
The vast majority of MABS isolates were resistant to moxifloxacin and ciprofloxacin, as 
previously reported (Yang et al., 2003; Chua et al., 2015). Studies investigating the activities 
in vitro of different generations of quinolones against clinical and reference strains of rapidly 
     
growing mycobacteria found high levels of resistance, confirming our results (de Moura et al., 
2012; Maurer et al., 2014; Ravnholt et al., 2018). 
In South Korea, prior research reported that almost all MABS isolates were resistant to 
ciprofloxacin and moxifloxacin (Lee et al., 2015; Jeong et al., 2017). Based on these findings, 
the treatment effects of moxifloxacin and ciprofloxacin seem to be limited. 
Susceptibility to macrolides varied widely depending on the subspecies. One drawback 
pertinent to M. abscessus is the possible occurrence of inducible resistance to clarithromycin 
(Jayasingam et al., 2017). This is caused by the presence of an active erythromycin resistance 
methylase (erm) gene as is the case in most strains of subsp. abscessus and bolletii (Nash et 
al., 2009). In the subsp. massiliense, the erm(41) gene is inactive (truncated) and consequently 
this subspecies is not affected by inducible resistance. As expected, all M. abscessus subsp. 
abscessus and M. abscessus subsp. bolletii that presented WT erm(41) gene were associated, 
in the microdilution test, with the transition from complete susceptibility to clarithromycin, at 
first reading (5 days), to resistance, at day 14.   
We found that the subsp. abscessus had a 94% inducible resistance rate. Contrary to the low 
susceptibility to clarithromycin observed in subsp. abscessus and bolletii, 100% of massiliense 
isolates were susceptible to clarithromycin. These findings highlight the importance of using 
different treatment strategies for the three subspecies and the consequent need for precise 
differentiation between the three subspecies. 
In agreement with others (Yang et al., 2003; Park et al., 2008; Kim et al., 2010; Bastian et al., 
2011; Koh et al., 2011) our M. abscessus isolates were characterized by high resistance rates 
to the majority of antibiotics. The use of macrolides is therefore suitable only for the treatment 
of infections due to M. abscessus subsp. massiliense and for those M. abscessus that present 
the T28C mutation. These data are in agreement with the more favorable clinical outcome 
reported for patients infected by M. abscessus subsp. massiliense in comparison with other M. 
abscessus subspecies (Koh et al., 2011).  
The treatment of MABS pulmonary infections is an emerging challenge in patients with cystic 
fibrosis. Multidrug therapy for prolonged durations is required and carries the significant 
burden of drug-related toxicity, cost and selective pressure for multidrug resistant bacteria. 
International guidelines (British Thoracic Society (BTS), United States Cystic Fibrosis 
Foundation (US CFF) and the European Cystic Fibrosis Society (ECFS)) (Floto et al., 2016; 
Haworth et al., 2017) acknowledge that clinical and in vitro data to support treatment regimens 
are limited, particularly in children, and the presence of differences in susceptibility of the 
Mycobacterium abscessus subspecies confirms the need for accurate identification and the 
     
usefulness of susceptibility testing performed in microdilution with MIC determination 
(Ravnholt et al., 2018; Shaw et al., 2019).  
In conclusion, differences in drug susceptibility patterns of MABS could explain the different 
treatment outcomes among the three subspecies. The goal of antimicrobial susceptibility 
testing is to predict whether patients treated with specific antibiotics are likely to be cured for 
their infections. Since antibiotic susceptibilities differ substantially among strains in different 
geographical locations and clinical settings, local antibiotic susceptibility data are very helpful 
in choosing the treatment for infections, especially in critical patients. Prospective studies of 
MABS species are needed to understand the association between different antimicrobial 
susceptibility testing results and clinical outcome.  
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Table 1. Drug susceptibility profiles of the subspecies abscessus, bolletii and  massiliense.  
  
Susceptible Intermediate Resistant 
abscessus 
(202) 
bolletii 
 (52) 
massiliense 
 (60) 
abscessus 
 (202) 
bolletii  
(52) 
massiliense 
(60) 
abscessus 
(202) 
bolletii  
(52) 
massiliense 
(60) 
P-value 
Antibiotics* 
No. of 
isolates (%) 
No. of 
isolates (%) 
No. of isolates 
(%) 
No. of isolates 
(%) 
No. of 
isolates (%) 
No. of isolates 
(%) 
No. of isolates 
(%) 
No. of 
isolates (%) 
No. of isolates 
(%) 
SXT 29 (14%) 19 (37%) 29 (48%) 0 0 0 173 (86%) 33 (63%) 31 (52%) <0.001 
LZD 190 (94%) 52 (100%) 56 (93%) 12 (6%) 0 4 (7%) 0 0 0 1 
CIP 46 (13%) 6 (11,5%) 0 45 (22%) 19 (36,5%) 23 (38%) 111 (55%) 27 (52%) 37 (62%) 0.5454 
IMI 53 (26%) 12 (23%) 10 (17%) 71 (35%) 26 (50%) 35 (58%) 78 (39%) 14 (27%) 15 (25%) 0.0729 
MXF 39 (20%) 14 (27%) 19 (32%) 40 (20%) 12 (23%) 0 123 (60%) 26 (50%) 41 (68%) 0.1386 
FOX 80 (40%) 18 (35%) 35 (75%) 115 (57%) 34 (65%) 25 (25%) 7 (3%) 0 0 0.2636 
AMI 200 (99%) 52 (100%) 60 (100%) 0 0 0 2 (1%) 0 0 1 
DOX 1 (1%) 0 2 (3,5%) 16 (8%) 6 (11,5%) 2 (3,5%) 185 (91%) 46 (88.5%) 56 (93%) 0.6488 
CLA on day 5 202 (100%) 52 (100%) 60 (100%) 0 0 0 0 0 0 1 
CLA on day 14 12 (6%) 0 60 (100%) 0 0 0 190 (94%) 52(100%) 0 <0.001 
*SXT: trimethoprim/sulfamethoxazole, LZD: linezolid, CIP: ciprofloxacin, IMI: imipenem, MXF: moxifloxacin, FOX: cefoxitin, AMI: amikacin, DOX: 
doxycyclin 
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Table 2. Correlation of clarithromycin MICs with the presence of mutations in erm(41) and rrl. *truncated 
 
 
  
Clarithromycin MIC (µg/mL)   erm (41) rrl 
≤ 0,06 0,12 0,25 0,5 1 2 4 8 16 32    
  
M. abscessus subsp. abscessus (202) 
 
/ / / / / /  83 107 /  WT WT 
1 / 1 10 / / / / / /  mut WT 
 
M. abscessus subsp. bolletii (52)  / / / / / / / 6 46 /  WT WT 
 
M. abscessus subsp. massiliense (60)  18 6 19 17 / /  / / /  *trunc. WT 
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Table 3. MIC 50/90  
 abscessus bolletii massiliense 
Antibiotics* 
MIC 50 
(μg/ml) 
MIC 90 
(μg/ml) 
MIC 50 
(μg/ml) 
MIC 90 
(μg/ml) 
MIC 50 
(μg/ml) 
MIC 90 
(μg/ml) 
SXT 8 8 8 8 4 8 
LZD 8 8 8 8 1 8 
CIP 4 4 4 4 4 4 
IMI 8 32 8 16 8 16 
MXF 4 8 2 8 4 8 
FOX 32 64 32 32 16 32 
AMI 2 4 2 4 4 8 
DOX 16 16 16 16 16 16 
CLA on day 
5 0,25 1 0,5 1 0,12 0,5 
CLA on day 
14 16 16 16 16 0,25 0,5 
 
*SXT: trimethoprim/sulfamethoxazole, LZD: linezolid, CIP: ciprofloxacin, IMI: imipenem, 
MXF: moxifloxacin, FOX: cefoxitin, AMI: amikacin, DOX: doxycyclin 
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Figure 1: MABS subspecies and duration of infection in chronically infected patients 
 
